SCHEMBL33708

SCHEMBL33708

C=C1C(C)C2C(Cc3ccccc3)NC(=O)C23C(OC(C)=O)/C=C/C(C)(O)CC(C)C/C=C\C3C1O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA3 P0DMS8 1/20 1.00
NR0B1 P51843 1/20 0.79
NPC1 O15118 2/20 0.49
LMNA P02545 1/20 0.49
SLC2A1 P11166 1/20 0.49
SLC2A2 P11168 1/20 0.49
SLC2A3 P11169 1/20 0.49
SLC2A4 P14672 1/20 0.49
MAPK1 P28482 1/20 0.49
RAB9A P51151 1/20 0.49
SLC2A9 Q9NRM0 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
HIF1A Q16665 1/20 0.49
PAX8 Q06710 1/20 0.49
CCR5 P51681 1/20 0.45
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
ABCB1 P08183 7/20 0.33
CYP3A4 P08684 1/20 0.32
ALDH1A1 P00352 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30119602 1.00 ADORA3 (1.00) ADORA3NR0B1NPC1LMNASLC2A1
SCHEMBL33772 0.89 ADORA3 (0.80) ADORA3NR0B1NPC1LMNASLC2A1
Cytochalasin D SCHEMBL33529 0.88 NR0B1 (1.00) ADORA3NR0B1NPC1LMNASLC2A1
Cytochalasin D SCHEMBL33528 0.88 NR0B1 (1.00) ADORA3NR0B1NPC1LMNASLC2A1
Cytochalasin D SCHEMBL16502284 0.88 NR0B1 (1.00) ADORA3NR0B1NPC1LMNASLC2A1
Cytochalasin D SCHEMBL31734099 0.88 NR0B1 (1.00) ADORA3NR0B1NPC1LMNASLC2A1
Cytochalasin D SCHEMBL12648577 0.88 NR0B1 (1.00) ADORA3NR0B1NPC1LMNASLC2A1
Cytochalasin D SCHEMBL29375699 0.88 NR0B1 (1.00) ADORA3NR0B1NPC1LMNASLC2A1
Cytochalasin D SCHEMBL25847004 0.88 NR0B1 (1.00) ADORA3NR0B1NPC1LMNASLC2A1
SCHEMBL15531832 0.87 ADORA3 (0.77) ADORA3NR0B1NPC1LMNASLC2A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 282 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111249445-B Cytochalasin H soft capsule and preparation method thereof 广东医科大学 2022-11-15 CN claimed
EP-2919795-B1 SOLUBILIZATION OF ANTIGEN COMPONENTS FOR REMOVAL FROM TISSUES UNIV CALIFORNIA (US) 2021-06-30 EP claimed
CN-111249445-A Cytochalasin H soft capsule and preparation method thereof 广东医科大学 2020-06-09 CN claimed
US-9920320-B2 Methods of modulating compliance of the trabecular meshwork THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2018-03-20 US claimed
CN-105925646-A Method for preparing cytochalasin H from mangrove endophytic fungi 广东医学院 2016-09-07 CN claimed
US-20160215285-A1 METHODS OF MODULATING COMPLIANCE OF THE TRABECULAR MESHWORK THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2016-07-28 US claimed
US-9206423-B2 Methods of modulating compliance of the trabecular meshwork THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2015-12-08 US claimed
EP-2919795-A1 SOLUBILIZATION OF ANTIGEN COMPONENTS FOR REMOVAL FROM TISSUES The Regents of The University of California (US) 2015-09-23 EP claimed
US-20140187607-A1 METHODS OF MODULATING COMPLIANCE OF THE TRABECULAR MESHWORK THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2014-07-03 US claimed
CN-103816149-A Application of cytochalasin H in preparation of Parkinson's disease resistant drugs UNIV YANGZHOU 2014-05-28 CN claimed
WO-2014077934-A1 SOLUBILIZATION OF ANTIGEN COMPONENTS FOR REMOVAL FROM TISSUES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2014-05-22 WO claimed
US-20090143279-A1 Methods and compositions for treating metabolic disorders PRESIDENT AND FELLOWS OF HARVARD COLLEGE 2009-06-04 US claimed
US-20090062904-A1 STENT COATING ICON INTERVENTIONAL SYSTEMS, INC. 2009-03-05 US claimed
WO-2008156654-A2 CYTOSKELETON MODULATORS FOR TREATING METABOLIC DISORDERS MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2008-12-24 WO claimed
US-5994388-A Cytochalasin and isoindolinone derivatives as inhibitors of angiogenesis THE CHILDREN'S MEDICAL CENTER CORPORATION (US) 1999-11-30 US claimed
WO-1998041205-A1 CYTOCHALASIN AND ISOINDOLINONE DERIVATIVES AS INHIBITORS OF ANGIOGENESIS THE CHILDREN'S MEDICAL CENTER CORPORATION (US) 1998-09-24 WO claimed
US-20260070124-A1 METHOD FOR FORMING A TUBE MIRUS LLC (US) 2026-03-12 US disclosed
US-12569595-B2 Bioprosthetic tissue preparation EDWARDS LIFESCIENCES CORPORATION (US) 2026-03-10 US disclosed
EP-0226585-A1 CULTIVATING APPARATUS. MACRI LESLEY JEAN (AU) 1987-07-01 EP disclosed
WO-1986001368-A1 CULTIVATING APPARATUS MACRI, LESLEY, JEAN (AU) 1986-03-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260070124-A1 METHOD FOR FORMING A TUBE NIT2, NFE2L2, DUOX2 ADORA3 3123/4885NR0B1 2547/4885NPC1 2580/4885
US-12569595-B2 Bioprosthetic tissue preparation BCHE, LNPEP, DPEP1 ADORA3 2883/4885NR0B1 3919/4885NPC1 2049/4885
US-20090143279-A1 Methods and compositions for treating metabolic disorders PC, PCK2, CS ADORA3 2528/4885NR0B1 3104/4885NPC1 335/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.